NCT04330144

Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Gangnam Severance Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Accepted

Summary

There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. * Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group. * Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment). * Safety comparison: Safety verification by identifying major side effects in the HCQ group."

Conditions

• Contact Person From COVID-19 Confirmed Patient

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine as post exposure prophylaxis	1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
OTHER	Others(No intervention)	No treatment. Close monitoring and quarantine.

Timeline

• Start date: 2020-04-01
• Primary completion: 2020-06-29
• Completion: 2020-06-29
• First posted: 2020-04-01
• Last updated: 2021-08-09

Locations

1 site across 1 country: South Korea